A step forward for stem cell therapy

Aline Betancourt, research associate professor with the Tulane Center for Stem Cell Research and Regenerative Medicine, developed a technique to produce standardized stem cells that will turn off the body’s inflammatory response. Credit: Paula Burch-Celentano

(Medical Xpress) -- A new study shows the potential of a method to prepare stem cells that may provide relief from a painful diabetes complication. Aline Betancourt of the Tulane University Center for Stem Cell Research and Regenerative Medicine, with colleagues at Tulane and the Ochsner Clinic Foundation, developed a new treatment using modified stem cells to control inflammation.

The study results released on Monday (July 9) in the journal Translational Medicine suggest that the use of stem cells specially prepared to turn off the body’s inflammatory response represent a promising new therapeutic strategy for diabetic peripheral neuropathy that should be further investigated.

About 70 percent of diabetics have neuropathy (nerve damage) resulting from the disease, according to the National Institutes of Health. Severe peripheral neuropathy causes excruciating pain in the toes, feet, legs, hands or arms. Even a tiny amount of external pressure can be excruciating. is considered a major culprit.

Previous studies have proven mesenchymal stem cells (MSCs) are safe and effective in treating inflammatory diseases. MSCs, which are taken from adult donors, can give rise to a large number of tissue types such as bone, fat and cartilage.

“The problem,” Betancourt explains, “is that the current methods for preparing these cells yield a mixed pool of undefined cells that aren’t consistently effective in the clinic. Our laboratory developed a new method that results in a consistent, uniform MSC population and optimizes their anti-inflammatory effects. We call these cells MSC2s.”

When the researchers tested the MSC2 cells on mice with peripheral neuropathy, they saw a significant improvement in inflammation and other symptoms — as much as 40 percent for the MSC2 group over the mice that received no treatment. At best, there was only 14 percent improvement in those administered conventional MSCs.

add to favorites email to friend print save as pdf

Related Stories

Sniffing out a new source of stem cells

Jun 13, 2011

A team of researchers, led by Emmanuel Nivet, now at the Salk Institute for Biological Studies, La Jolla, has generated data in mice that suggest that adult stem cells from immune system tissue in the smell-sensing region ...

Researchers make breakthrough in stem cell research

Feb 13, 2012

(Medical Xpress) -- University of Queensland scientists have developed a world-first method for producing adult stem cells that will substantially impact patients who have a range of serious diseases.

Turning on adult stem cells may help repair bone

Jan 25, 2008

The use of a drug to activate stem cells that differentiate into bone appears to cause regeneration of bone tissue and be may be a potential treatment strategy for osteoporosis, according to a report in the February 2008 ...

Recommended for you

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.